Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 68 Records) |
| Query Trace: Lung Neoplasms and VEGF[original query] |
|---|
| SNP and Haplotype Analysis of Vascular Endothelial Growth Factor (VEGF) Gene in Lung Cancer Patients of Kashmir. Asian Pacific journal of cancer prevention : APJCP 2017 07 18 (7): 1799-1804. Naikoo Niyaz A, Afroze Dil, Rasool Roohi, Shah Sonaullah, Ahangar A G, Bhat Imtiyaz A, Qasim Iqbal, Siddiqi Mushtaq A, Shah Zafar |
| KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 Feb . Sullivan I, Salazar J, Arqueros C, Andrés M, Sebio A, Majem M, Szafranska J, Martínez E, Páez D, López-Pousa A, Baiget M, Barnadas |
| Association between VEGF Gene Polymorphisms and the Susceptibility to Lung Cancer: An Updated Meta-Analysis. BioMed research international 2018 2018 9271215. Yang Fengming, Qin Zhiqiang, Shao Chuchu, Liu Weitao, Ma Ling, Shu Yongqian, Shen H |
| Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma. Oncology letters 2018 Aug 16 (2): 2105-2112. Yuan Xiao-Han, Yang Jie, Wang Xin-Yue, Zhang Xiao-Ling, Qin Ting-Ting, Li K |
| LIN28B enhanced tumorigenesis in an autochthonous KRAS-driven lung carcinoma mouse model. Oncogene 2018 3 37 (20): 2746-2756. Meder Lydia, König Katharina, Dietlein Felix, Macheleidt Iris, Florin Alexandra, Ercanoglu Meryem S, Rommerscheidt-Fuss Ursula, Koker Mirjam, Schön Gisela, Odenthal Margarete, Klein Florian, Büttner Reinhard, Schulte Johannes H, Heukamp Lukas C, Ullrich Roland |
| Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. Angiogenesis 2019 Apr . Sullivan Ivana, Riera Pau, Andrés Marta, Altés Albert, Majem Margarita, Blanco Remei, Capdevila Laia, Barba Andrés, Barnadas Agustí, Salazar Julia |
| The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. Current treatment options in oncology 2019 2 20 (3): 21. Perdrizet Kirstin, Leighl Natasha |
| Differential Efficacy of Anti-VEGF Antibodies Based on Sex and Race in a Diverse Cohort of Advanced Nonsquamous Non-Small Cell Lung Cancer. American journal of clinical oncology 2019 Nov . Sukrithan Vineeth, Barbaro Alexander, Chergui Adel, Ko Brian, Lin Juan, Cheng Haiying, Goel Sanj |
| Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Current oncology reports 2020 Sep 22 (12): 119. Peravali Monica, Wang Haijun, Kim Chul, Veytsman Iri |
| First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. Journal of cancer research and clinical oncology 2020 Jul . Landre Thierry, Des Guetz Gaetan, Chouahnia Kader, Duchemann Boris, Assié Jean-Baptiste, Chouaid Christ |
| Correlation of gene polymorphisms of vascular endothelial growth factor with grade and prognosis of lung cancer. BMC medical genetics 2020 Apr 21 (1): 86. Liu Changjiang, Zhou Xuetao, Zhang Zefeng, Guo Ya |
| Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis. Medicine 2020 Jan 99 (3): e18771. Zhou Kenan, Zhao Shishun, Guo Wenlai, Ding L |
| Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung cancer (Amsterdam, Netherlands) 2020 Nov 151 20-24. Yamamoto N, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Yamanaka T, Tanaka M, Takahashi K, Fukuoka |
| Pretreatment to Posttreatment Hypoxia Inducible Factor-1? Ratios as a Potentially Predictive Marker for First-Line Treatment in Nonsmall Cell Lung Cancer Patients without Known Driver Mutations. Genetic testing and molecular biomarkers 2020 12 24 (12): 798-803. Hu Mingming, Zhang Tongmei, Gu Meng, Li Jie, Zhang Hongmei, Wang Qunhui, Hu Fanbin, Yang Yuan, Li Baol |
| Relationship between vascular endothelial growth factor -2578C > a gene polymorphism and lung cancer risk: a meta-analysis. BMC medical genetics 2020 Jan 21 (1): 17. Zhao Hui-Liu, Yu Jia-Hua, Huang Ling-Sha, Li Pei-Zhang, Lao Ming, Zhu Bo, Ou Ch |
| Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer cell 2021 Jul . Zhou Qing, Xu Chong-Rui, Cheng Ying, Liu Yun-Peng, Chen Gong-Yan, Cui Jiu-Wei, Yang Nong, Song Yong, Li Xiao-Ling, Lu Shun, Zhou Jian-Ying, Ma Zhi-Yong, Yu Shi-Ying, Huang Cheng, Shu Yong-Qian, Wang Zhen, Yang Jin-Ji, Tu Hai-Yan, Zhong Wen-Zhao, Wu Yi-Lo |
| ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. Cancer cell 2021 8 39 (9): 1178-1180. Le Xiuning, Nilsson Monique B, Robichaux Jacqulyne P, Heymach John |
| Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study. Frontiers in oncology 2021 11 695038. Jantus-Lewintre Eloisa, Massutí Sureda Bartomeu, González Larriba José Luis, Rodríguez-Abreu Delvys, Juan Oscar, Blasco Ana, Dómine Manuel, Provencio Pulla Mariano, Garde Javier, Álvarez Rosa, Maestu Inmaculada, Pérez de Carrión Ramón, Artal Ángel, Rolfo Christian, de Castro Javier, Guillot Mónica, Oramas Juana, de Las Peñas Ramón, Ferrera Lioba, Martínez Natividad, Serra Òlbia, Rosell Rafael, Camps Carl |
| Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. International journal of cancer 2021 5 149 (5): 1121-1128. Yu Xiaoqing, Sheng Jiamin, Pan Guoqiang, Fan Y |
| Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer. Scientific reports 2021 Oct 11 (1): 19596. Cho Su Han, Yoon Shinkyo, Lee Dae Ho, Kim Sang-We, Kim Kwone |
| VEGF single nucleotide polymorphisms predict improved outcome in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Journal of chemotherapy (Florence, Italy) 2022 3 35 (1): 53-62. Qi Huijie, Zhang Wenxin, Wang Yan, Ge Mengxi, Wang Tianxiao, Zhang Liudi, Zhong Mingkang, Shi Xiaojin, Liang Xiaohua, Zhan Qiong, Li Qun |
| Ischemic stroke in a patient with EGFR-mutated non-small-cell lung cancer after treatment with ramucirumab. Thoracic cancer 2022 10 13 (23): 3412-3414. Chen Guo-Yu, Cheng Wen-Chien, Tu Chih-Y |
| Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma. Journal of cancer research and clinical oncology 2023 9 . Wenting Liu, Junling Xia, Qingwu Du, Jingya Wang, Ting Mei, Tingting Q |
| A retrospective study of the efficacy of combined EGFR?TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR?TKI monotherapy for PD?L1?positive EGFR?mutant non?small cell lung cancer: North Japan Lung Cancer Study Group 2202. Oncology letters 2023 7 26 (2): 334. Minehiko Inomata, Yosuke Kawashima, Ryota Saito, Daisuke Morinaga, Hitomi Nogawa, Masamichi Sato, Yohei Suzuki, Satoru Yanagisawa, Takashi Kikuchi, Daisuke Jingu, Naruo Yoshimura, Toshiyuki Harada, Eisaku Miyauc |
| Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFRnon-small-cell lung cancer. Translational lung cancer research 2023 7 12 (6): 1167-1184. Makoto Nishio, Shinji Atagi, Koichi Goto, Yukio Hosomi, Takashi Seto, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshige Yoshioka, Naoyuki Nogami, Makoto Maemondo, Seisuke Nagase, Isamu Okamoto, Noboru Yamamoto, Yuriko Igawa, Kosei Tajima, Masahiro Fukuoka, Nobuyuki Yamamoto, Kazuto Nish |
| RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome. Clinical lung cancer 2023 4 . Makoto Nishio, Luis Paz-Ares, Martin Reck, Kazuhiko Nakagawa, Edward B Garon, Sanjay Popat, Matteo Ceccarelli, Hillary T Graham, Carla Visseren-Grul, Silvia Novel |
| Uses of Vascular Endothelial Growth Factor C as a Lung Adenocarcinoma Prognostic Biomarker. World journal of oncology 2023 3 14 (1): 51-59. Chen Shi, Pan Ting Yu, Wu Xiao, Li Tian, Wei Yu, He Hai Lang, Zhou Xian Mei, Wang Qian, Zhu Ji Pi |
| Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer. Anticancer research 2023 1 43 (2): 713-724. Ikeuchi Nobumitsu, Igata Fumiyasu, Kinoshita Eriko, Kawabata Toshiaki, Tan Ibun, Osaki Yusuke, Otsuka Rikako, On Rintaro, Ikeda Takato, Nakao Akira, Sasaki Tomoya, Aoyama Takashi, Hirano Ryosuke, Harada Taishi, Ebi Noriyuki, Fujita Masaki, Inoue Hiroyu |
| Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis. ESMO open 2024 8 9 (9): 103660. Z Piotrowska, B Y Yeap, J F Gain |
| Ivonescimab: First Approval. Drugs 2024 7 . Sohita Dhill |
- Page last reviewed:Feb 1, 2024
- Content source: